Shimono J, Miyoshi H, Kamimura T, Eto T, Miyagishima T, Sasaki Y, et al. Clinicopathological features of primary splenic follicular lymphoma. Ann Hematol. 2017;96:2063-2070 pubmed publisher

Wang D, Zheng Y, Zeng D, Yang Y, Zhang X, Feng Y, et al. Clinicopathologic characteristics of HIV/AIDS-related plasmablastic lymphoma. Int J STD AIDS. 2017;28:380-388 pubmed publisher

Soon G, Ow G, Chan H, Ng S, Wang S. Primary cardiac diffuse large B-cell lymphoma in immunocompetent patients: clinical, histologic, immunophenotypic, and genotypic features of 3 cases. Ann Diagn Pathol. 2016;24:40-6 pubmed publisher

Gallo M, Cacheux V, Vincent L, Bret C, Tempier A, Guittard C, et al. Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14. Virchows Arch. 2016;469:697-706 pubmed

Neumann L, Mueller M, Moos V, Heller F, Meyer T, Loddenkemper C, et al. Mucosal Inducible NO Synthase-Producing IgA+ Plasma Cells in Helicobacter pylori-Infected Patients. J Immunol. 2016;197:1801-8 pubmed publisher

Banat G, Tretyn A, Pullamsetti S, Wilhelm J, Weigert A, Olesch C, et al. Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma. PLoS ONE. 2015;10:e0139073 pubmed publisher

Ribera Cortada I, Martinez D, Amador V, Royo C, Navarro A, Beà S, et al. Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype. Mod Pathol. 2015;28:1435-47 pubmed publisher

Williams J, van Niekerk S, Human S, van Wilpe E, Venter M. Pathology of fatal lineage 1 and 2 West Nile virus infections in horses in South Africa. J S Afr Vet Assoc. 2014;85:1105 pubmed publisher

Song M, Chung J, Lee G, Cho S, Hong J, Shin D, et al. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era. Leuk Res. 2015;39:211-5 pubmed publisher

Song M, Chung J, Lee J, Yang D, Kim I, Shin D, et al. High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy. Int J Hematol. 2015;101:140-7 pubmed publisher

Knutson S, Warholic N, Johnston L, Klaus C, Wigle T, Iwanowicz D, et al. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. PLoS ONE. 2014;9:e111840 pubmed publisher

Bellas C, Garcia D, Vicente Y, Kilany L, Abraira V, Navarro B, et al. Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma. PLoS ONE. 2014;9:e98169 pubmed publisher

Li Y, Yimamu M, Wang X, Zhang X, Mao M, Fu L, et al. Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression. Int J Hematol. 2014;99:79-86 pubmed publisher

Caramuta S, Lee L, Ozata D, Akçakaya P, Georgii Hemming P, Xie H, et al. Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma. Blood Cancer J. 2013;3:e152 pubmed publisher

Wong K, Gascoyne D, Brown P, Soilleux E, Snell C, Chen H, et al. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. Leukemia. 2014;28:362-72 pubmed publisher

Cho I, Lee H, Yoon S, Ryu K, Ko Y, Kim W, et al. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. BMC Cancer. 2020;20:120 pubmed publisher

Huang S, Nong L, Wang W, Liang L, Zheng Y, Liu J, et al. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma. Diagn Pathol. 2019;14:81 pubmed publisher

Lu T, Wu S, Cai D, Hong T, Zhang Y, Gao H, et al. Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma. BMC Cancer. 2019;19:553 pubmed publisher

Chiche J, Reverso Meinietti J, Mouchotte A, Rubio Patiño C, Mhaidly R, Villa E, et al. GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. Cell Metab. 2019;29:1243-1257.e10 pubmed publisher

Zambello R, Crimì F, Lico A, Barilà G, Branca A, Guolo A, et al. Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI. Ann Hematol. 2019;98:679-689 pubmed publisher

Wu S, Zhou Y, Hua H, Zhang Y, Zhu W, Wang Z, et al. Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma. BMC Cancer. 2018;18:997 pubmed publisher

Shinojima N, Fujimoto K, Makino K, Todaka K, Yamada K, Mikami Y, et al. Clinical significance of polyglutamylation in primary central nervous system lymphoma. Acta Neuropathol Commun. 2018;6:15 pubmed publisher

McHugh D, Caduff N, Barros M, Rämer P, Raykova A, Murer A, et al. Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression. Cell Host Microbe. 2017;22:61-73.e7 pubmed publisher

Oliveira C, Maciel Guerra H, Kucko L, Hirama E, Brilhante A, Quevedo F, et al. Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma. Diagn Pathol. 2017;12:3 pubmed publisher

Zhang X, Shi Y, Weng Y, Lai Q, Luo T, Zhao J, et al. The truncate mutation of Notch2 enhances cell proliferation through activating the NF-κB signal pathway in the diffuse large B-cell lymphomas. PLoS ONE. 2014;9:e108747 pubmed publisher

Zlobec I, Karamitopoulou E, Terracciano L, Piscuoglio S, Iezzi G, Muraro M, et al. TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. PLoS ONE. 2010;5:e14282 pubmed publisher